Latigo reports Q3 2026 results, names new CEO, adds opioid arm to Phase 3 trialNov 5Quarterly updateCollegium Pharmaceutical, IncLatigo Biotherapeutics
Collegium cuts 2026 revenue guidance on weaker Nucynta generic pricingAug 6Quarterly updateCollegium Pharmaceutical, Inctapentadol
Zevra reports Q2 2026 results as MIPLYFFA revenue grows and EU review continuesAug 5Quarterly updatearimoclomolZevra Therapeutics, Inc.